| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 869766 | 923032-37-5 | sc-364427 sc-364427A | 5 mg 10 mg | $245.00 $428.00 | 1 | |
BAY 869766 inhibits MCM5 by directly targeting the protein's ATPase activity, crucial for its function in DNA replication initiation. This inhibition disrupts the unwinding of DNA, essential for replication, leading to the stalling of DNA synthesis. The specific mechanism involves competitive binding to the ATP-binding site, preventing ATP hydrolysis. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
MEK162 (Binimetinib) achieves inhibition of MCM5 indirectly through the blockade of MEK, which is upstream of key regulatory pathways controlling MCM5 phosphorylation and activation. This interference prevents the necessary activation signals from reaching MCM5, impairing its ability to initiate DNA replication. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
GDC-0973 (Cobimetinib) inhibits MCM5 by targeting the MEK/ERK signaling pathway, which plays a critical role in the phosphorylation and subsequent activation of MCM5. The inhibition of this pathway leads to a decrease in MCM5 activity, effectively blocking the progression of DNA replication. | ||||||
AS703026 | 1236699-92-5 | sc-364412 sc-364412A | 5 mg 10 mg | $80.00 $130.00 | ||
AS703026 inhibits MCM5 indirectly by suppressing the activity of MEK, which is involved in the phosphorylation-based activation of MCM5 essential for the commencement of DNA replication. This suppression results in the reduced phosphorylation of MCM5, diminishing its replication initiation capability. | ||||||